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eply
e thank Drs. Ntim and Hundley for their interest in our paper
1) and their comments regarding the role of cardiac magnetic
esonance (CMR) in the evaluation of cardiac complications of
ancer therapy. We agree that CMR has a well-defined and
xpanding role in the evaluation and management of cardiac
isease in general, with specific value in cardiovascular structure,
unction, and physiology (2). The use of CMR in cardiotoxicity,
owever, has only been evaluated in a preliminary fashion. One
tudy (3) with a limited number of patients and without biopsy
orrelation, suggested that CMR could be used as a prognosticator
f future cardiomyopathy. A 10-patient case series evaluated the
alue of CMR in confirming the presence of left ventricular
ysfunction and demonstrated late gadolinium enhancement in
atients with cardiomyopathy. Delayed enhancement CMR was
lso used to demonstrate abnormalities in patients with late-onset
ardiomyopathy in isolated case reports (4,5).
The ability of delayed gadolinium enhancement CMR to
iagnose myocardial pathology makes it an attractive method to
valuate patients at risk for antineoplastic cardiotoxicity. However,
s of yet there have been no studies correlating findings of CMR
o endomyocardial biopsies, which is the gold standard. In addi-
ion, the total number of patients studied to this day remains very
mall. Because of this lack of data we do not routinely use CMR
t M. D. Anderson Cancer Center for the purpose of screening or
ollowing patients with cardiotoxicity.
In conclusion, whereas we felt it would be premature to include
MR in a state-of-the-art paper, we feel strongly that this
echnology merits further investigation and certainly has the
otential to benefit patients with cardiotoxicity related to cancer
reatment.Edward T. H. Yeh, MD
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